Legal & General Group Plc Has $15.62 Million Position in Krystal Biotech, Inc. $KRYS

Legal & General Group Plc lowered its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 3.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 63,361 shares of the company’s stock after selling 2,454 shares during the period. Legal & General Group Plc owned 0.22% of Krystal Biotech worth $15,621,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the company. New Age Alpha Advisors LLC acquired a new position in Krystal Biotech in the fourth quarter worth approximately $301,000. Hantz Financial Services Inc. increased its holdings in Krystal Biotech by 27.1% in the fourth quarter. Hantz Financial Services Inc. now owns 371 shares of the company’s stock worth $91,000 after buying an additional 79 shares during the last quarter. William Blair Investment Management LLC increased its holdings in Krystal Biotech by 152.1% in the fourth quarter. William Blair Investment Management LLC now owns 376,340 shares of the company’s stock worth $92,783,000 after buying an additional 227,038 shares during the last quarter. Coldstream Capital Management Inc. acquired a new position in Krystal Biotech in the fourth quarter worth approximately $228,000. Finally, Global Retirement Partners LLC increased its holdings in Krystal Biotech by 788.9% in the fourth quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock worth $39,000 after buying an additional 142 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Price Performance

Shares of KRYS stock opened at $298.10 on Tuesday. The stock has a market cap of $8.79 billion, a P/E ratio of 39.85 and a beta of 0.50. Krystal Biotech, Inc. has a one year low of $124.00 and a one year high of $319.48. The stock has a fifty day moving average price of $278.39 and a 200 day moving average price of $261.87.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, May 4th. The company reported $1.83 EPS for the quarter, topping the consensus estimate of $1.45 by $0.38. The firm had revenue of $116.36 million during the quarter, compared to analysts’ expectations of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. Equities research analysts anticipate that Krystal Biotech, Inc. will post 7.83 EPS for the current year.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $263.21, for a total value of $6,580,250.00. Following the completion of the transaction, the insider directly owned 1,403,155 shares of the company’s stock, valued at $369,324,427.55. This trade represents a 1.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP John Charles Thomas sold 642 shares of the firm’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $302.03, for a total value of $193,903.26. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Evercore reaffirmed an “outperform” rating and set a $300.00 target price on shares of Krystal Biotech in a research report on Tuesday, May 5th. Weiss Ratings raised Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, April 9th. Chardan Capital upped their target price on Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. HC Wainwright reaffirmed a “buy” rating and set a $310.00 target price on shares of Krystal Biotech in a research report on Monday. Finally, Guggenheim upped their target price on Krystal Biotech from $224.00 to $284.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Ten research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $324.11.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.